Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Innovate UK

Investor type Entrepreneurship Program

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 580
Average round size
info
The average size of a deal this fund participated in
$932K
Portfolio companies 475
Rounds per year 38.67
Lead investments 228
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.18
Exits 26
Key employees 7
Stages of investment
Grant

Areas of investment

  • Health Care
  • Software
  • Biotechnology
  • Medical Device
  • Medical
Summary

Innovate UK appeared to be the Corporate Investor, which was created in 2007. The fund was located in Europe if to be more exact in United Kingdom. The main department of described Corporate Investor is located in the Swindon.

Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular fund investment industries, there are Software, Pharmaceutical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Among the most popular portfolio startups of the fund, we may highlight F2G, Sky Medical Technology, Genomics. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low.

The standard case for the fund is to invest in rounds with 1-2 partakers. Despite the Innovate UK, startups are often financed by Newable Private Investing, Mercia Fund Managers, Scottish Investment Bank. The meaningful sponsors for the fund in investment in the same round are SBRI Healthcare, Wayra, Longwall Venture Partners. In the next rounds fund is usually obtained by Entrepreneur First, EASME - EU Executive Agency for SMEs, Oxford Technology Management.

The higher amount of exits for fund were in 2019. Deals in the range of 1 - 5 millions dollars are the general things for fund. The average startup value when the investment from Innovate UK is 100 thousands - 1 million dollars. This Innovate UK works on 25 percentage points less the average amount of lead investments comparing to the other organizations. Considering the real fund results, this Corporate Investor is 43 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 13-24 deals per year. The important activity for fund was in 2018.

The overall number of key employees were 6.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Innovate UK:
Typical Co-investors
Innovate UK is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Innovate UK:

Funds with similar focus

Funds from United Kingdom
Funds with similar focus located in United Kingdom:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Stemnovate

Biotechnology
$1M04 Aug 2022 South Cambridgeshire, England, United Kingdom

Eleven Therapeutics

Biotechnology
Medical
Product Research
Therapeutics
$22M02 Aug 2022 Tel Aviv, Tel Aviv, Israel

Built AI

Artificial Intelligence
Commercial Real Estate
Machine Learning
Software
01 Aug 2022 London, England, United Kingdom

T-DAB.AI

Analytics
Artificial Intelligence
Machine Learning
21 Jul 2022 London, England, United Kingdom

Paragraf

Advanced Materials
Electronics
Industrial Engineering
Manufacturing
Semiconductor
$753K19 Jul 2022 Huntingdonshire, England, United Kingdom

Awakn Life Sciences

Biotechnology
Health Care
Life Science
18 Jul 2022 Toronto, Ontario, Canada

Hypetex

Industrial
Manufacturing
Service Industry
$160K14 Jul 2022 London, England, United Kingdom

Dyman Advanced Materials

$882K08 Jul 2022 Stockton-on-Tees, England, United Kingdom

PhysioMedics

Health Care
Insurance
Software
04 Jul 2022 Edinburgh, Scotland, United Kingdom
News
Camallergy Awarded £1.1 M Funding Under Innovate UK Biomedical Catalyst Award for Novel Peanut Allergy Treatment

– Cambridge Allergy Ltd (“Camallergy” or “the Company”), a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced it has been awarded £1.1M funding under the Innovate UK Biomedical Catalyst Award program administered by Innovate UK, the United Kingdom’s research and innovation agency.
– The £1.1M in non-dilutive funding will be used to accelerate the Company’s peanut allergy immunotherapy, CA002, for planned Phase 3 clinical trials.
– The project commences in the first quarter of 2021, and as part of the project’s success, the Company intends to file its investigation new drug application with the FDA and submit a clinical trials application to the MHRA and EMA.

CN Bio Awarded Innovate UK Grant to Develop Single and Multi-organ Models for COVID-19 Research

– CN Bio announced a grant from Innovate UK to develop human-relevant MPS to advance investigations into SARS-CoV-2 infection.
– The funding will be used to develop and test advanced cell culture models that represent different regions of the lung and subsequently linking these models to other organ systems, such as liver and gut, to inform the rapid development of novel therapeutics.
– The fast-moving nature of the COVID-19 pandemic directs additional pressure onto current drug discovery and development processes, which can be limited by misrepresentative in vivo models that cause a large proportion of new medicines to fail when taken to clinical trials.
– To circumvent this, CN Bio is developing single and multi-organ COVID-19 models to investigate virology and immunology throughout the body, with a prolonged viable cell culture time for extended studies.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Innovate UK?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: